Incentives Aid Smoking Cessation Across Populations
By Lori Solomon HealthDay Reporter
TUESDAY, Jan. 14, 2025 -- There is high-certainty evidence that incentives improve smoking cessation rates at long-term follow-up across populations, according to a review published online Jan. 13 in the Cochrane Database of Systematic Reviews.
Caitlin Notley, Ph.D., from Norwich Medical School at the University of East Anglia in the United Kingdom, and colleagues conducted a systematic review to assess the long-term effects of incentives and contingency management programs for smoking cessation in mixed and pregnant populations. Incentives included cash payments, self-deposits, or vouchers for goods and groceries, offered directly or collected and redeemable online.
Based on 48 mixed-population studies that allocated 21,924 participants to smoking cessation incentive schemes or control conditions, the researchers found that the pooled risk ratio (RR) for quitting with incentives at the longest follow-up (six months or longer) was 1.52 (I2 = 23 percent; 39 studies, 18,303 participants; high-certainty evidence) compared with controls. Results were similar when excluding seven studies that offered an incentive for cessation at long-term follow-up (RR, 1.46; I2 = 26 percent; 32 studies, 15,082 participants), suggesting the impact of incentives continues for at least some time after incentives cease. Total financial amount of incentives varied considerably between trials, from zero (self-deposits) to a range from $45 to $1,185, but there was no clear difference in effect between trials offering low or high total value of incentives nor those encouraging redeemable self-deposits. In an analysis including 14 studies of 4,314 pregnant people, pooled data showed an RR at the longest follow-up (up to 48 weeks postpartum) of 2.13 (I2 = 31 percent; 13 studies, 3,942 participants; high-certainty evidence), in favor of incentives.
"It's not that these people could have quit anyway and then were paid and decided to do so," coauthor Jamie Hartmann-Boyce, Ph.D., from the University of Massachusetts Amherst, said in a statement. "A lot of people in these studies have tried to quit many times, they really want to quit and weren't able to do so, and this helped them."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-01-15 06:00
Read more
- GLP-1 Zepbound Is Approved As First Drug For Sleep Apnea
- Diabetes Drug Protects Against Skin Cancer, New Research Says
- Sleep Deprivation Lets Intrusive Memories, Bad Thoughts Into the Mind
- Pertussis Cases Surging in the United States
- Review Shows Inverse Link Between Fluoride Exposure and Children's IQ
- Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions